Bengt Simonsson

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Hehlmann, Ruediger; Cortes, Jorge E.; Zyczynski, Teresa; Gambacorti-Passerini, Carlo et al.

Ingår i American Journal of Hematology, s. 46-54, 2019

• DOI för Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
• Ladda ner fulltext (pdf) av Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Hoffmann, V S; Baccarani, M; Hasford, J; Castagnetti, F et al.

Ingår i Leukemia, s. 593-601, 2017

• DOI för Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

PATRONES DE CAMBIO DE LOS INHIBIDORES DE LA TIROSINA CINASA BCR-ABL1 EN PACIENTES CON LMC EN FASE CRÓNICA EN LA PRÁCTICA CLÍNICA RUTINARIA ESTUDIO SIMPLICITY

Perez Encinas, M.; Goldberg, S. L.; Michallet, M.; Hehlmann, R. et al.

Ingår i Haematologica, s. 285-285, 2017

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Goldberg, Stuart L.; Cortes, Jorge E.; Gambacorti-Passerini, Carlo; Hehlmann, Ruediger et al.

Ingår i American Journal of Hematology, s. 1214-1223, 2017

• DOI för First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY
• Ladda ner fulltext (pdf) av First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Ingår i Leukemia Research, s. 95-103, 2016

• DOI för Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Hehlmann, Ruediger; Cortes, Jorge E.; Zyczynski, Teresa; Gambacorti-Passerini, Carlo et al.

Ingår i American Journal of Hematology, s. 46-54, 2019

• DOI för Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
• Ladda ner fulltext (pdf) av Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Hoffmann, V S; Baccarani, M; Hasford, J; Castagnetti, F et al.

Ingår i Leukemia, s. 593-601, 2017

• DOI för Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

PATRONES DE CAMBIO DE LOS INHIBIDORES DE LA TIROSINA CINASA BCR-ABL1 EN PACIENTES CON LMC EN FASE CRÓNICA EN LA PRÁCTICA CLÍNICA RUTINARIA ESTUDIO SIMPLICITY

Perez Encinas, M.; Goldberg, S. L.; Michallet, M.; Hehlmann, R. et al.

Ingår i Haematologica, s. 285-285, 2017

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Goldberg, Stuart L.; Cortes, Jorge E.; Gambacorti-Passerini, Carlo; Hehlmann, Ruediger et al.

Ingår i American Journal of Hematology, s. 1214-1223, 2017

• DOI för First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY
• Ladda ner fulltext (pdf) av First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Ingår i Leukemia Research, s. 95-103, 2016

• DOI för Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Plasma Proteomics In Chronic Myeloid Leukemia Patients Before And After Initiation Of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity And Loss Of Angiogenic Stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, H. et al.

Ingår i Haematologica, s. 730-730, 2016

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

Pfirrmann, M.; Baccarani, M.; Saussele, S.; Guilhot, J. et al.

Ingår i Leukemia, s. 48-56, 2016

• DOI för Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Padula, William V.; Larson, Richard A.; Dusetzina, Stacie B.; Apperley, Jane F. et al.

Ingår i Journal of the National Cancer Institute, 2016

• DOI för Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
• Ladda ner fulltext (pdf) av Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Imatinib Discontinuation And Tki Switching Patterns In The Retrospective And Prospective Cohorts In Simplicity, A Study Of Chronic-Phase Chronic Myeloid Leukemia (Cp-Cml) Patients (Pts) In Routine Clinical Practice

Zyczynski, T.; Khoury, J.; Goldberg, S.; Mauro, M. et al.

Ingår i Value in Health, 2016

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta et al.

Ingår i European Journal of Haematology, s. 243-250, 2015

• DOI för Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
• Ladda ner fulltext (pdf) av Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Hoffmann, V. S.; Baccarani, M.; Hasford, J.; Lindoerfer, D. et al.

Ingår i Leukemia, s. 1336-1343, 2015

• DOI för The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

ANALYSIS OF TREATMENT AND OUTCOME DATA OF 2904 PATIENTS FROM THE EUTOS POPULATION-BASED REGISTRY

Hoffmann, V. S.; Baccarani, M.; Hasford, J.; Lindoerfer, D. et al.

Ingår i Haematologica, s. 181-181, 2015

CARDIOVASCULAR (CV)-RELATED HOSPITALIZATION IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY

Paquette, R.; Mauro, M.; Simonsson, Bengt; Abruzzese, E. et al.

Ingår i Haematologica, s. 437-437, 2015

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

Pfirrmann, Markus; Hasford, Joerg; Saussele, Susanne; Turkina, Anna et al.

Ingår i Blood, 2015

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Hoffmann, Verena Sophia; Baccarani, Michele; Hasford, Joerg; Lindoerfer, Doris et al.

Ingår i Blood, 2015

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Christiansson, Lisa; Mustjoki, Satu; Simonsson, Bengt; Olsson-Strömberg, Ulla et al.

Ingår i EuPA Open Proteomics, s. 37-47, 2014

• DOI för The use of multiplex platforms for absolute and relative protein quantification of clinical material

The Eutos Population Based Registry - Incidences of CML Across Europe

Hoffmann, V.; Lindoerfer, D.; Thaler, J.; Labar, B. et al.

Ingår i Haematologica, s. 72-72, 2014

Overall Survival and Prognosis in 2190 Patients with First-Line Imatinib Treatment Considering Death Due to Chronic Myeloid Leukaemia as the Only Event

Pfirrmann, M.; Saussele, S.; Baccarani, M.; Guilhot, J. et al.

Ingår i Haematologica, s. 531-532, 2014

The Eutos Population-Based Registry: Evaluation of Baseline Characteristics and First Treatment Choices Of 2983 Newly Diagnosed Chronic Myeloid Leukemia (Cml) Patients from 20 European Countries

Lindoerfer, D.; Hoffmann, V. S.; Rosti, G.; Castagnetti, F. et al.

Ingår i Haematologica, s. 238-239, 2014

TYROSINE KINASE INHIBITOR (TKI) SWITCHING: EXPERIENCE FROM SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS IN CLINICAL PRACTICE

Hehlmann, R.; Cortes, J.; Gambacorti-Passerini, C.; Goldberg, S. L. et al.

Ingår i Haematologica, s. 328-329, 2014

Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Koskenvesa, Perttu; Kreutzman, Anna; Rohon, Peter; Pihlman, Markus et al.

Ingår i European Journal of Haematology, s. 413-420, 2014

• DOI för Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia

Pfirrmann, Markus; Saussele, Susanne; Baccarani, Michele; Guilhot, Joelle et al.

Ingår i Blood, 2014

Incidence of CML in Europe -- a Comparison of 19 European Countries with US SEER Data

Hoffmann, Verena S.; Lindoerfer, Doris; Thaler, Josef; Boris, Labar et al.

Ingår i Blood, 2014

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Baccarani, Michele; Hoffmann, Verena Sophia; Rosti, Gianantonio; Castagnetti, Fausto et al.

Ingår i Blood, 2014

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Larson, Richard A.; Conti, Rena; Padula, William V.; Apperley, Jane F. et al.

Ingår i Blood, 2014

Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)

Mauro, Michael; Gambacorti-Passerini, Carlo; Goldberg, Stuart L.; Cortes, Jorge E. et al.

Ingår i Blood, 2014

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Christiansson, Lisa; Söderlund, Stina; Svensson, Emma; Mustjoki, Satu et al.

Ingår i PLOS ONE, 2013

• DOI för Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
• Ladda ner fulltext (pdf) av Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Höglund, Martin; Sandin, Fredrik; Hellstrom, Karin; Bjoreman, Mats et al.

Ingår i Blood, s. 1284-1292, 2013

• DOI för Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Mustjoki, S.; Richter, J.; Barbany, G.; Ehrencrona, H. et al.

Ingår i Leukemia, s. 1520-1526, 2013

• DOI för Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Overall survival and prognosis in patients with chronic myeloid leukaemia allocated to first-line imatinib treatment - new results from the EUTOS "In-Study" registry

Pfirrmann, M.; Saussele, S.; Baccarani, M.; Guilhot, J. et al.

Ingår i Onkologie (Basel), s. 100-100, 2013

The EUTOS CML score aims to support clinical decision-making

Hoffmann, Verena; Baccarani, Michele; Hasford, Joerg; Guilhot, Joelle et al.

Ingår i Blood, s. 2966-2967, 2012

• DOI för The EUTOS CML score aims to support clinical decision-making

Medical registries represent vital patient interests and should not be dismantled by stricter regulation

Hansson, Mats G; Simonsson, Bengt; Feltelius, Nils; Forsberg, Joanna Stjernschantz et al.

Ingår i Cancer Epidemiology, s. 575-578, 2012

• DOI för Medical registries represent vital patient interests and should not be dismantled by stricter regulation

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

Guilhot, Joelle; Baccarani, Michele; Clark, Richard E.; Cervantes, Francisco et al.

Ingår i Blood, s. 5963-5971, 2012

• DOI för Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

Parental Age, Family Size, and Offspring's Risk of Childhood and Adult Acute Leukemia

Larfors, Gunnar; Hallböök, Helene; Simonsson, Bengt

Ingår i Cancer Epidemiology, Biomarkers and Prevention, s. 1185-1190, 2012

• DOI för Parental Age, Family Size, and Offspring's Risk of Childhood and Adult Acute Leukemia

Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Simonsson, Bengt; Gedde-Dahl, Tobias; Markevarn, Berit; Remes, Kari et al.

Ingår i Blood, s. 3228-3235, 2011

• DOI för Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Lindqvist, Camilla; Christiansson, Lisa; Thörn, Ingrid; Mangsbo, Sara et al.

Ingår i Immunology, s. 296-306, 2011

• DOI för Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Lindqvist, Camilla A.; Christiansson, Lisa H.; Simonsson, Bengt; Enblad, Gunilla et al.

Ingår i Immunology, s. 371-376, 2010

• DOI för T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib

Olsson-Strömberg, Ulla; Hermansson, Monica; Lundan, Tuija; Ohm, Anne-Charlotte et al.

Ingår i European Journal of Haematology, s. 399-404, 2010

• DOI för Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib

A population based registry in chronic myeloid leukemia (CML), a network of registries covering "representative" areas or regions of Europe (< 10 millions people)

Schrotz-King, P.; Hasford, J.; Lindoerfer, D.; Piccolo, C. et al.

Ingår i Onkologie (Basel), s. 147-147, 2010

Second-Generation BCR-ABL Kinase Inhibitors in CML

Simonsson, Bengt; Porkka, Kimmo; Richter, Johan

Ingår i New England Journal of Medicine, s. 1673-1673, 2010

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Baccarani, Michele; Rosti, Gianantonio; Castagnetti, Fausto; Haznedaroglu, Ibrahim et al.

Ingår i Blood, s. 4497-4504, 2009

• DOI för Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

Mustjoki, S.; Ekblom, M.; Arstila, T. P.; Dybedal, I. et al.

Ingår i Leukemia, s. 1398-1405, 2009

• DOI för Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

Feldman, E. J.; Cortes, J.; DeAngelo, D. J.; Holyoake, T. et al.

Ingår i Leukemia, s. 1707-1711, 2008

• DOI för On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia

Gupta, Manu; Milani, Lili; Hermansson, Monica; Simonsson, Bengt et al.

Ingår i Biochemical and Biophysical Research Communications - BBRC, s. 848-851, 2008

• DOI för Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia

Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients

Hagberg, Anette; Olsson-Strömberg, Ulla; Wickenberg-Bolin, Ulrika; Göransson, Hanna et al.

Ingår i Leukemia Research, s. 931-938, 2007

• DOI för Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

Ottmann, Oliver; Dombret, Hervé; Martinelli, Giovanni; Simonsson, Bengt et al.

Ingår i Blood, s. 2309-2315, 2007

• DOI för Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up

Simonsson, Bengt

Ingår i Annals of Oncology, 2007

• DOI för Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Brune, Mats; Castaigne, Sylvie; Catalano, John; Gehlsen, Kurt et al.

Ingår i Blood, s. 88-96, 2006

• DOI för Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Klinische Forschung im „European LeukemiaNet”

Saussele, S.; Adam, K.; Hochhaus, A.; Béné, M. C. et al.

Ingår i Deutsche Medizinische Wochenschrift, s. 2423-2426, 2006

• DOI för Klinische Forschung im „European LeukemiaNet”

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Druker, Brian J.; Guilhot, Francois; O'Brien, Stephen G.; Gathmann, Insa et al.

Ingår i New England Journal of Medicine, s. 2408-2417, 2006

• DOI för Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Baccarani, Michele; Saglio, Giuseppe; Goldman, John; Hochhaus, Andreas et al.

Ingår i Blood, s. 1809-1820, 2006

• DOI för Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML).

Simonsson, B; Kloke, O; Stahel, R A

Ingår i Ann Oncol, 2005

Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.

Simonsson, Bengt; Oberg, Gunnar; Bjoreman, Mats; Bjorkholm, Magnus et al.

Ingår i Acta Haematol, s. 155-62, 2005

Epidemiology of chronic myeloid leukaemia: an update

Höglund, Martin; Sandin, Fredrik; Simonsson, Bengt

Ingår i Annals of Hematology, 2015

• DOI för Epidemiology of chronic myeloid leukaemia: an update

European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Baccarani, Michele; Deininger, Michael W.; Rosti, Gianantonio; Hochhaus, Andreas et al.

Ingår i Blood, s. 872-884, 2013

• DOI för European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

Baccarani, Michele; Cortes, Jorge; Pane, Fabrizio; Niederwieser, Dietger et al.

Ingår i Journal of Clinical Oncology, s. 6041-6051, 2009

• DOI för Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

Imatinib or dasatinib treatment of chronic myeloid leukemia reduces circulating myeloid-derived suppressor cells but increases their CD40 expression

Christiansson, Lisa; Söderlund, Stina; Hjorth-Hansen, Henrik; Höglund, Martin et al.